Skip to main content

Advertisement

Table 4 Correlations between baseline parameters and the reduction of body weight or HbA1c at 2 year

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters Reduction of body weight Reduction of HbA1c
   Multivariate p value   Multivariate p value
  r p value   r p value  
Age −0.080 0.601   −0.197 0.190  
Male −0.131 0.390   −0.052 0.732  
BMI 0.474 0.001 0.018 0.134 0.382  
WC 0.111 0.012 0.255 0.055 0.776  
Duration of DM 0.076 0.651   −0.003 0.984  
SBP −0.106 0.490   0.003 0.982  
DBP −0.007 0.963   0.222 0.138  
FPG −0.115 0.451   −0.066 0.664  
HbA1c 0.145 0.341   0.738 <0.001 <0.001
LDL-C 0.137 0.383   0.420 0.005 0.701
TG 0.156 0.319   0.202 0.188  
HDL-C 0.024 0.880   −0.137 0.374  
AST 0.073 0.660   0.044 0.790  
ALT 0.002 0.988   0.232 0.120  
sCPR 0.222 0.152   0.108 0.542  
Insulin dose 0.345 0.023 0.027 −0.078 0.617  
Insulin dose U/kg 0.022 0.152   −0.102 0.509  
Eating behavior −0.078 0.731   0.126 0.576  
Previous treatment
Insulin 0.118 0.441   −0.176 0.242  
BG −0.153 0.316   −0.053 0.725  
SU −0.098 0.521   −0.250 0.094 0.996
αGI −0.035 0.819   −0.006 0.969  
TZD 0.190 0.212   −0.191 0.204  
DPP4i 0.048 0.752   0.169 0.263  
Glinide −0.060 0.697   0.161 0.285  
  1. Reduction of body weight or HbA1c from baseline to 2 year was analyzed with baseline clinical parameters.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.